公开(公告)号：US20230212513A1

公开(公告)日：2023-07-06

申请号：US18009192

申请日：2021-06-17

Applicant: The Children's Medical Center Corporation

Inventor： Ashlee J. Conway ,  Tolulope O. Rosanwo ,  Thomas E. Williamson ,  Trista E. North ,  George Q. Daley

IPC: C12N5/078 ,  A61K31/573 ,  A61K31/727 ,  A61K35/16 ,  A61K35/545 ,  A61K38/18 ,  A61K38/20 ,  A61K38/28 ,  A61K38/40

CPC classification number: C12N5/0641 ,  A61K31/573 ,  A61K31/727 ,  A61K35/16 ,  A61K35/545 ,  A61K38/18 ,  A61K38/1816 ,  A61K38/202 ,  A61K38/28 ,  A61K38/40 ,  C12N2500/25 ,  C12N2501/125 ,  C12N2501/14 ,  C12N2501/2303 ,  C12N2501/39 ,  C12N2501/91

Abstract: The invention described herein is directed to compositions and methods for inducing red blood cell (RBC) differentiation. Additionally, provided herein are methods of treating a subject in need thereof by administering the induced RBC described herein.

公开(公告)号：US20170258853A1

公开(公告)日：2017-09-14

申请号：US15452338

申请日：2017-03-07

Applicant: AAL Scientifics, Inc.

Inventor： Piero Anversa

IPC: A61K35/39 ,  C12N5/071

CPC classification number: A61K35/39 ,  A61K35/28 ,  C12N5/0676 ,  C12N5/0678 ,  C12N2501/105 ,  C12N2501/115 ,  C12N2501/12 ,  C12N2501/125 ,  C12N2501/14 ,  C12N2533/52

Abstract: The disclosure relates to stem cells and their therapeutic use in the treatment and/or prevention of pancreatic diseases or disorders. Provided herein are compositions comprising c-kit positive pancreatic stem cells and methods of preparing and using c-kit positive pancreatic stem cells for the treatment and/or prevention of pancreatic diseases or disorders.

公开(公告)号：US20170240860A1

公开(公告)日：2017-08-24

申请号：US14925346

申请日：2015-10-28

Applicant: Anthrogenesis Corporation

Inventor： Mohammad A. Heidaran ,  Xiaokui Zhang ,  Lin Kang ,  Andrew Zeitlin ,  Vanessa Voskinarian-Berse ,  Stewart Abbot

IPC: C12N5/078

CPC classification number: C12N5/0641 ,  C12N2500/99 ,  C12N2501/105 ,  C12N2501/11 ,  C12N2501/125 ,  C12N2501/135 ,  C12N2501/14 ,  C12N2501/145 ,  C12N2501/22 ,  C12N2501/2303 ,  C12N2501/2306 ,  C12N2501/2311 ,  C12N2501/26 ,  C12N2501/999

Abstract: Provided herein are methods of producing erythrocytes from hematopoietic cells, particularly hematopoietic cells from placental perfusate in combination with hematopoietic cells from umbilical cord blood, wherein the method results in accelerated expansion and differentiation of the hematopoietic cells to more efficiently produce administrable erythrocytes. Further provided herein is a bioreactor in which hematopoietic cell expansion and differentiation takes place.

公开(公告)号：US20170000779A1

公开(公告)日：2017-01-05

申请号：US15018302

申请日：2016-02-08

Applicant: Anthrogenesis Corporation ,  Celgene Corporation ,  Signal Pharmaceuticals

Inventor： Robert J. Hariri ,  David Stirling ,  Laure A. Moutouh-De Parseval ,  Kyle W.H. Chan

IPC: A61K31/454

CPC classification number: A61K31/454 ,  A61K2035/124 ,  C12N5/0639 ,  C12N5/0642 ,  C12N5/0647 ,  C12N2501/125 ,  C12N2501/14 ,  C12N2501/22 ,  C12N2501/23 ,  C12N2501/25 ,  C12N2501/385 ,  C12N2501/70 ,  C12N2506/02

Abstract: The present invention relates to methods of modulating mammalian stem cell and progenitor cell differentiation. The methods of the invention can be employed to regulate and control the differentiation and maturation of mammalian, particularly human stem cells along specific cell and tissue lineages. The methods of the invention relate to the use of certain small organic molecules to modulate the differentiation of stem or progenitor cell populations along specific cell and tissue lineages, and in particular, to the differentiation of embryonic-like stem cells originating from a postpartum placenta or for the differentiation of early progenitor cells to a granulocytic lineage. Finally, the invention relates to the use of such differentiated stem or progenitor cells in transplantation and other medical treatments.

Abstract translation: 本发明涉及调节哺乳动物干细胞和祖细胞分化的方法。 本发明的方法可用于调节和控制特定细胞和组织谱系中哺乳动物，特别是人干细胞的分化和成熟。 本发明的方法涉及某些小有机分子在特定细胞和组织谱系中调节干细胞或祖细胞群的分化的用途，特别是涉及来源于产后胎盘的胚胎样干细胞的分化或 用于将早期祖细胞分化成粒细胞谱系。 最后，本发明涉及这种分化的干细胞或祖细胞在移植和其他医学治疗中的用途。

公开(公告)号：US09428732B2

公开(公告)日：2016-08-30

申请号：US13706067

申请日：2012-12-05

Applicant: Primorigen Biosciences, Inc.

Inventor： Niels-Bjarne Woods ,  Roger Ronn ,  Carolina Guibentif

IPC: C12N5/078 ,  C12N5/0783 ,  C12N5/0789 ,  C12N5/0781 ,  A61K35/14

CPC classification number: C12N5/0634 ,  A61K35/14 ,  A61K35/28 ,  A61K2035/124 ,  C12N5/0635 ,  C12N5/0636 ,  C12N5/0646 ,  C12N5/0647 ,  C12N2500/24 ,  C12N2500/38 ,  C12N2501/02 ,  C12N2501/04 ,  C12N2501/065 ,  C12N2501/125 ,  C12N2501/14 ,  C12N2501/145 ,  C12N2501/15 ,  C12N2501/155 ,  C12N2501/165 ,  C12N2501/2302 ,  C12N2501/2307 ,  C12N2501/2315 ,  C12N2501/26 ,  C12N2501/385 ,  C12N2501/71 ,  C12N2501/80 ,  C12N2501/999 ,  C12N2506/02 ,  C12N2506/11 ,  C12N2506/45

Abstract: Compositions and methods that employ various combinations of such factors as retinoic acid signaling inhibitors, antioxidants, BMP4, VEGF, prostaglandin E2 pathway stimulants, TPO, SCF, FLT-3, EPO, TGFβ1, p38 MAPK inhibitors, beta adrenergic receptor agonists, cell cycle inhibitors, RXR agonists, Cripto, and chromatin remodelers to drive differentiation of pluripotent stem cells towards primitive blood cells. Uses of such primitive blood cells are provided.

Abstract translation: 使用视黄酸信号传导抑制剂，抗氧化剂，BMP4，VEGF，前列腺素E2途径刺激剂，TPO，SCF，FLT-3，EPO，TGFβ1，p38 MAPK抑制剂，β肾上腺素能受体激动剂，细胞周期的各种组合的组合物和方法 抑制剂，RXR激动剂，Cripto和染色质重组体，以驱动多能干细胞分化为原始血细胞。 提供了这种原始血细胞的使用。

公开(公告)号：US09409964B2

公开(公告)日：2016-08-09

申请号：US14264975

申请日：2014-04-29

Applicant: Alexion Pharmaceuticals, Inc.

Inventor： Katherine S. Bowdish ,  Shana Frederickson ,  Mark Renshaw

IPC: A61K35/14 ,  C07K16/00 ,  C07K7/00 ,  C07K14/505 ,  C07K14/52 ,  C07K16/12 ,  C07K16/18 ,  C07K16/46 ,  C12N5/078 ,  A61K39/00 ,  A61K39/40

CPC classification number: C07K14/505 ,  A61K39/00 ,  A61K39/40 ,  A61K2039/505 ,  C07K14/524 ,  C07K16/00 ,  C07K16/005 ,  C07K16/1282 ,  C07K16/18 ,  C07K16/46 ,  C07K2317/21 ,  C07K2317/55 ,  C07K2317/565 ,  C07K2317/74 ,  C07K2318/10 ,  C07K2319/00 ,  C07K2319/036 ,  C07K2319/30 ,  C07K2319/75 ,  C12N5/0641 ,  C12N2501/14 ,  C12N2506/11

Abstract: Antibodies or fragments thereof having CDR regions replaced or fused with biologically active peptides are described. Flanking sequences may optionally be attached at one or both the carboxy-terminal and amino-terminal ends of the peptide in covalent association with adjacent framework regions. Compositions containing such antibodies or fragments thereof are useful in therapeutic and diagnostic modalities.

公开(公告)号：US20160194607A1

公开(公告)日：2016-07-07

申请号：US14989310

申请日：2016-01-06

Applicant: Université Pierre et Marie Curiè (Paris 6) ,  Etablissement Français du Sang ,  ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS

Inventor： Luc Douay ,  Marie-Catherine Giarratana

IPC: C12N5/0789

CPC classification number: C12N5/0647 ,  C12N5/0641 ,  C12N2500/25 ,  C12N2500/90 ,  C12N2501/125 ,  C12N2501/14 ,  C12N2501/145 ,  C12N2501/155 ,  C12N2501/165 ,  C12N2501/2303 ,  C12N2501/2306 ,  C12N2501/26 ,  C12N2501/91

Abstract: A method for the production of cells of the hematopoietic lineage includes culturing hematopoietic stem cells (HSC) or embryonic bodies with a cell culture medium (the cell culture medium includes insulin at a concentration of from 1 to 50 μg/ml, transferrin at a concentration of from 100 μg/ml to 2000 μg/ml and plasma or serum at a concentration of from 1% to 30%) under conditions allowing producing cells of the hematopoietic lineage; and collecting cells of the hematopoietic lineage.

Abstract translation: 用于制造造血谱系细胞的方法包括用细胞培养基培养造血干细胞（HSC）或胚胎体（细胞培养基包括浓度为1至50μg/ ml的胰岛素，浓度为的转铁蛋白 在100μg/ ml至2000μg/ ml的浓度范围内，血浆或血清浓度为1％至30％），在允许产生造血谱系细胞的条件下; 并收集造血谱系的细胞。

公开(公告)号：US20160145579A1

公开(公告)日：2016-05-26

申请号：US14942259

申请日：2015-11-16

Applicant: Yael Porat ,  Valentin Fulga ,  Svetlana Porozov ,  Adina Belleli

Inventor： Yael Porat ,  Valentin Fulga ,  Svetlana Porozov ,  Adina Belleli

IPC: C12N5/071 ,  A61K35/44

CPC classification number: C12N5/0692 ,  A61K35/44 ,  A61K2035/124 ,  C12N5/0607 ,  C12N5/0634 ,  C12N2501/14 ,  C12N2501/165 ,  C12N2501/23 ,  C12N2501/33 ,  C12N2501/39 ,  C12N2501/392 ,  C12N2501/599 ,  C12N2501/91 ,  C12N2506/11 ,  C12N2510/00 ,  C12N2533/52 ,  C12N2533/54

Abstract: Provided are methods for producing progenitor/precursor cells from a population of initiating cells (ICP) that have a density of less than 1.072 g/ml and at least 25% of which are CD31Bright by in vitro stimulating the ICP with different factors.

公开(公告)号：US20160137981A1

公开(公告)日：2016-05-19

申请号：US14897599

申请日：2014-06-11

Applicant: KYOTO UNIVERSITY

Inventor： Shinya Yamanaka ,  Yoshinori Yoshida ,  Masatoshi Nishizawa

IPC: C12N5/0789 ,  C07K14/65 ,  C12Q1/68

CPC classification number: C12N5/0647 ,  C07K14/65 ,  C12N5/0696 ,  C12N2501/105 ,  C12N2501/115 ,  C12N2501/125 ,  C12N2501/14 ,  C12N2501/145 ,  C12N2501/155 ,  C12N2501/165 ,  C12N2501/2303 ,  C12N2501/2306 ,  C12N2501/2311 ,  C12N2501/26 ,  C12N2506/45 ,  C12N2510/00 ,  C12Q1/6881 ,  C12Q2600/158 ,  G01N33/56966

Abstract: A method for producing hematopoietic stem cells and/or hematopoietic progenitor cells from pluripotent stem cells is described. The method includes a step of culturing pluripotent stem cells in the presence of IGF2. A method is described for selecting an induced pluripotent stem cell(s) having high capacity to differentiate into hematopoietic stem cells and/or hematopoietic progenitor cells, or into blood cells, based on the expression level(s) of one or more genes such as TRIM58, CTSF, FAM19A5, and TCERG1L genes, or on the DNA methylation state(s) of the TRIM58, CSMD1, and/or FAM19A5 gene(s).

Abstract translation: 描述了从多能干细胞产生造血干细胞和/或造血祖细胞的方法。 该方法包括在IGF2存在下培养多能干细胞的步骤。 描述了一种基于一个或多个基因的表达水平来选择具有高分化成造血干细胞和/或造血祖细胞或血细胞的诱导多能干细胞的方法，例如 TRIM58，CTSF，FAM19A5和TCERG1L基因，或TRIM58，CSMD1和/或FAM19A5基因的DNA甲基化状态。

公开(公告)号：US20160068810A1

公开(公告)日：2016-03-10

申请号：US14888110

申请日：2014-05-15

Applicant: UNIVERSITY OF ROCHESTER

Inventor： James Palis ,  Samantha England ,  Ah Ram Kim

IPC: C12N5/078 ,  A61K35/18

CPC classification number: C12N5/0641 ,  A61K35/18 ,  C12N2500/36 ,  C12N2500/90 ,  C12N2501/125 ,  C12N2501/14 ,  C12N2501/33 ,  C12N2501/39 ,  C12N2506/02 ,  C12N2510/00

Abstract: The present invention provides a human cell population that can self-renew extensively and yet retain the capacity to differentiate into red blood cells (RBCs). These cells are referred to as extensively self-renewing erythroblasts (ESREs). The cells of the invention serve among other things as a renewable source of transfusable RBCs.

Abstract translation: 本发明提供了可以自我更新并且保持分化成红细胞（RBC）的能力的人类细胞群体。 这些细胞被称为广泛自我更新的成红细胞（ESRE）。 本发明的细胞可以用作可再生的可转染的RBC的来源。